Kornimate/medical-research-clean huggingface dataset:
htert immunotherapy alone or in combination with il-12 dna followed by electroporation in adults with solid tumors at high risk of relapse

Conditions: Breast Cancer; Lung Cancer; Pancreatic Cancer; Head and Neck Cancer; Ovarian Cancer; ColoRectal Cancer; Gastric Cancer; Esophageal Cancer; HepatoCellular Carcinoma

Summary: this is a phase i, open label study to evaluate the safety, tolerability, and immunogenicity of ino-1400 or ino-1401 alone or in combination with ino-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. subjects will be enrolled into one of ten treatment arms. subjects will be assessed according to standard of care. restaging and imaging studies will be performed to assess disease relapse per nccn guidelines. recist will be used to validate the findings in cases of relapse.


Eligibility criteria:
inclusion criteria: * 1. signed and dated written irb approved informed consent; * 2. males or females aged ≥18 years; * 3. subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse post definitive therapy at least 4 and no more than 24 weeks from completion of definitive therapy at the time of signing informed consent as described below for each indication: * breast carcinoma: * lung carcinoma: * pancreatic carcinoma: * head and neck squamous cell carcinoma: * ovarian cancer: * colorectal cancer * gastric and esophageal cancer * hepatocellular carcinoma exclusion criteria: * 1. previous treatment wth any tert or il-12 containing therapy, or any other dna immunotherapy; * 2. any concurrent condition requiring the continued or anticipated use of systemic steroids (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy (excludes low dose methotrexate). all other systemic corticosteroids must be discontinued at least 4 weeks prior to first study treatment; * 3. administration of any vaccine within 4 weeks of the first study treatment

Keywords: immunotherapy human telomerase reverse transcriptase (htert) breast neoplasms lung neoplasms pancreatic neoplasms high risk of relapse post definitive surgery post adjuvant therapy no evidence of disease
the impact of electroacupuncture combined with ngf on clinical effect and functional changes on ischemic stroke

Conditions: Ischemic Stroke

Summary: ischemic stroke is a common clinical disease, often accompanied by motor dysfunction and cognitive impairment. at present, clinical treatment for patients with ischemic stroke recovery is limited and ineffective. the emergence of ngf has surprised the field of neurorehabilitation, but the clinical effect is not satisfactory. the main problem is that ngf is a macromolecular material with a molecular weight of 13.4 kd, which is difficult to penetrate the blood brain barrier. a large number of previous studies in our team have found that electroacupuncture with specific stimulation mode can open the blood brain barrier and induce ngf into the brain。therefore, the purpose of this study is to investigate the effect of specific stimulation mode electroacupuncture combined with ngf treatment together with rehabilitation training on patients with ischemic stroke recovery period and to explore the mechanism of this combination therapy to improve brain function, which creates a new method and theoretical basis for nerve rehabilitation of integrated traditional chinese and western medicine.


Eligibility criteria:
inclusion criteria: * people with first-ever ischemic stroke confirmed by ct or/and mri; * 14 days to 6 months after stroke onset; * 50 years≤aged≤80 years; * 3≤modified rankin score (mrs)≤4, and mini-mental state examinations (mmse)\<27; * patients can accept treatment with ea and have good compliance; * patients have clear consciousness, pain perception and resolution ability to complete basic communication; * willing to participate and be randomized to one of the groups. exclusion criteria: * transient ischemic attack, subarachnoid hemorrhage, cerebral hemorrhage and other cerebrovascular diseases; * severe heart, liver, kidney dysfunction and severe coagulation dysfunction; * cerebral infarction caused by repeated recurrence of stroke, brain surgery or trauma, and brain tumors; * severe neurological deficits before stroke, such as visual and auditory impairment, aphasia, agnosia, severe hemiplegia, or affected limb function before stroke, such as cerebral palsy, polio, fracture, and mrs≥1; * diseases with affecting cognitive function such as congenital dementia, or alcohol, drug or substance abuse; * lactation, pregnancy or intend to be pregnant within 6 months; * needlesickness, needle phobia and skin infection at acupuncture site; * pacemaker, implantable cardioverter defibrillator carriers or conductive metallic foreign bodies in the body; * allergy to ngf; * currently enrolled in another clinical trial or participation in other clinical trials within the last 3 months.

Keywords: ischemic stroke convalescence electroacupuncture nerve growth factor
a study of ly3541860 in adult participants with moderately to severely active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the main purpose of this study is to evaluate the effects of ly3541860 in adult participants with moderately to severely active rheumatoid arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bdmard)or targeted synthetic disease-modifying antirheumatic drug (tsdmard). study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.


Eligibility criteria:
inclusion criteria: * have a diagnosis of adult-onset rheumatoid arthritis (ra) for at least 3 months prior to screening, as defined by the 2010 acr/eular classification criteria. * have moderately to severely active ra, at screening (visit 1) and baseline (visit 2), defined by the presence of * ≥6 swollen joints based on 66 joint count (and ≥4 swollen joints on 28 joint count), and * ≥6 tender joints based on 68 joint count (and ≥4 tender joints on 28 joint count). * have active synovitis in ≥1 joint, in hands or wrists, of the investigator choosing at screening, having an mri synovitis ramris score of ≥2 as determined from the central reading of the images. exclusion criteria: * have a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of * basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline. * have estimated glomerular filtration rate (egfr) of \<45 milliliter per minute (ml/minute) from serum creatinine using the chronic kidney disease epidemiology collaboration (ckd-epi) creatinine equation. * have a current or recent active infection. * have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to * poorly controlled diabetes or hypertension * chronic kidney disease stage 3a or b, 4, or 5 * symptomatic heart failure according to new york heart association class 2, 3, or 4 * myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before baseline * severe chronic pulmonary disease, for example, requiring oxygen therapy major chronic inflammatory disease or connective tissue disease other than ra, including but not limited to * systemic lupus erythematosus * psoriatic arthritis * axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis * reactive arthritis * gout * scleroderma * polymyositis * dermatomyositis * active fibromyalgia, or * multiple sclerosis * have received any prior b-cell targeted therapy (for example, anti-cd19 antibodies or anti-cd20 antibodies, such as rituximab). * received corticosteroids, opioids, conventional disease-modifying antirheumatic drug (cdmard), with changes in dose or have received janus kinase (jak) inhibitors within 28 days prior to the screening mri or plan on receiving these drugs during the study.
efficacy of prolotherapy and hydrodilatation for frozen shoulder

Conditions: Frozen Shoulder

Summary: objective: to determine whether ultrasound-guided intra-articular hypertonic dextrose and hydrodilatation improves pain and function in patients with frozen shoulder(fs)

setting: a medical center hospital. participants: subjects with primary fs with shoulder pain more than 3 months. interventions: participants randomly be assigned into a and b group: group a received ultrasound-guided hydrodilatation with hypertonic dextrose with a mixture of 2ml of 50%, 1ml of 2% lidocaine, and 6ml normative saline ; group b : ultrasound-guided hydrodilatation with 9 ml of normative saline and 1 ml of 2% lidocaine. main outcome measures: the primary outcome measure was the shoulder pain and disability index score. secondary outcomes were the vas of shoulder pain level, muscle power and angles of shoulder passive range of motion, including flexion, abduction, extension, external rotation, and internal rotation at pretreatment and weeks 2, 4, 8, 12 and 24 of post-treatment.

Eligibility criteria:
participants diagnosed with primary fs who had experienced shoulder pain for more than 6 months and a reduction \> 30° in passive rom of the affected shoulder in at least two directions (forward flexion, abduction, or external rotation) compared with the contralateral side were evaluated for eligibility. 23 subjects with any degree of tear or calcified tendinitis of rotator cuff tendons, previous shoulder surgery, previous intra-articular injection for the affected shoulder within 3 months of the study; or any secondary fs caused by metabolic, rheumatic, infectious arthritis, stroke, tumor, shoulder fracture/dislocation, or acute cervical radiculopathy were excluded. 23 -
gs regimen as the first-line chemotherapy in chinese advanced pc patients

Conditions: Pancreatic Cancer; Chemotherapy Effect; Chemotherapeutic Toxicity

Summary: gemcitabine plus s-1 (gs) prolonged progression-free survival (pfs) and greatly improved objective response rate (orr) as well as disease control rate (dcr) of asian patients with locally advanced and metastatic pancreatic cancer (pc). however, limited data of gs regimen exist on the efficacy and safety in the treatment of chinese patients with advanced pc. to assess the efficacy and safety of gemcitabine plus s-1 (gs regimen) as the first-line chemotherapy in chinese patients with advanced pc, we designed this prospective study.


Eligibility criteria:
inclusion criteria: * 1.histologically confirmed pancreatic adenocarcinoma 2.locally advanced or metastatic pc 3.chemotherapy-naïve 4.ecog performance status of 0 or 1 5. an adequate bone marrow, liver function and kidney function exclusion criteria: * 1.age ≥80 years 2.brain metastasis 3.with other malignancies 4.chronic diarrhea, cardiac disease, pregnancy or breast feeding
bimanual training in children with hemiplegia

Conditions: Hemiplegia; Cerebral Palsy; Children

Summary: a randomized control trial of bimanual training in children with hemiplegia. the protocols have been developed at columbia university to be child friendly and draws upon our experience since 1997 with constraint-induced movement therapy in children with cerebral palsy. the investigators will test the hypothesis that bimanual training (habit) will result in improved hand function in children with hemiplegia.

a new treatment involving bimanual (hand-arm bimanual intensive therapy (habit). the protocols have been developed at columbia university to be child friendly and draws upon our experience since 1997 with constraint-induced movement therapy in children with cerebral palsy. the investigators developed habit in 2004 as an alternative to constraint-therapy that avoids use of a restraint. the interventions are performed in a 15 day day-camp setting with several children and at least one therapist per child. the investigators have conducted 24 day camps to date since 2002, and are now collaborating with clinicians worldwide to expand our treatment availability. the aim is to promote the use of and improve the coordination of movement of both hands together. participation is free. please check out our website for more information: http://www.tc.edu/centers/cit/

Eligibility criteria:
inclusion criteria: \*willingness to agree to intervention and testing procedures and travel to the university for participation and testing exclusion criteria: * health problems not associated with cp * uncontrollable seizures * visual problems that would interfere with carrying out the intervention or testing * botulinum toxin therapy in the upper extremity musculature during the last six months or who wish to receive it within the period of study

Keywords: cerebral palsy constraint-induced therapy constraint-induced movement therapy cp hemiplegia hand forced use motor control children habit hand-arm bimanual intensive therapy bilateral training bimanual training functional therapy physical therapy occupational therapy intensive pediatric development upper extremity hemiplegic childhood stroke
learningrx cognitive training for tbi

Conditions: Traumatic Brain Injury (TBI)

Summary: the purpose of this investigation is to conduct a series of case studies on the impact of learningrx cognitive training on cognitive skills, brain structure, and daily functioning for participants with traumatic brain injury (tbi).

using a multiple baseline design across cases with start point randomization, the proposed study will examine the outcomes from learningrx one-on-one cognitive training across domains on standardized measures used to monitor treatment effectiveness for tbi.

Eligibility criteria:
inclusion criteria: * age 18+ previously diagnosed with tbi * living in the greater colorado springs area exclusion criteria: * no braces, metal implants, or claustrophobia that would contraindicate magnetic resonance imaging
evaluation of the effect of liposomal l-arg and vit c integration on mitochondrial function in patients with heart failure

Conditions: Heart Failure

Summary: pilot study to assess the effect of l-arg and vit c liposomal supplementation on mitochondrial function in patients with heart failure, through analysis of the viability of mitochondria isolated from peripheral blood of mononucleate cells (pbmc).

pilot, monocentric, national, non-pharmacological, prospective, double-blind randomized trial. the primary objective of this study is to assess the effect of liposomal l-arg and vit c supplementation on mitochondrial function in patients with heart failure, by analysis of the viability of mitochondria isolated from peripheral blood of mononucleate cells (pbmc). mitochondrial respiratory function of pbmc (in extensive lymphocytes and monocytes) is readily available. these cells are involved in many inflammatory diseases, including those driven by episodes of ischemia-reperfusion, which play a key role in cardiovascular alterations. in particular, the recruitment of t cells and myocardial infiltration are well described during ischemic and non-sischemic heart failure, so the mitochondrial function of pbmc could play a significant role in this immune disorderrelated during heart failure.

Eligibility criteria:
inclusion criteria: * age ≥18 years * diagnosis of heart failure with preserved ef 45%. exclusion criteria: * age \<18 years * left ventricular ejection fraction \<45% * valvular heart disease * previous myocardial infarction or coronary heart disease * hypertension * diabetes mellitus * intolerance to l-arginine and liposomal vitamin c * pregnancy * lactation.

Keywords: mitochondrial pbmc l-arg vit c
combining physical therapy with vestibular stimulation to improve postural stability in pusher's syndrome

Conditions: Pusher Syndrome

Summary: the study is evaluating the effect of combining galvanic vestibular stimulation (gvs) with standard physiotherapy treatment in patients admitted to a neurological rehabilitation unit with pusher syndrome (ps). patients will be randomised to receive standard physiotherapy treatment or standard treatment with gvs. perceived verticality data will also be collected and analysed on age-matched controls. this data will be used to compare these results with the patients with ps. the investigators hypothesis that gvs and standard physiotherapy treatment will lead to a greater improvement in functional ability and awareness of perceived verticality compared to standard physiotherapy alone.

pusher syndrome (ps) can be described as disordered balance and orientation which causes patients to perceive they are in an upright position when in fact they are positioned towards their affected side. these patients use their unaffected limbs to 'push' themselves away from their unaffected side in an attempt to correct their perceived postural alignment. ps is a common disorder and can affect 16% of stroke patients. patients with ps have shown to take longer to improve in rehabilitation than non-ps patients and tend to stay in hospital for longer. galvanic vestibular stimulation (gvs) involves passing a small electrical current behind the ear to stimulate the vestibular system to in-turn cause the head and body to move.

Eligibility criteria:
pusher inclusion criteria: * identified hemiparetic neglect - identified ps from a stroke or acquired brain injury (using the scale of contraversive pushing and the burke lateropulsion scale) * consenting to participate in the trial pusher exclusion criteria: * severe cognitive impairment * receptive aphasia * medical co-morbidities * opthalamic impairment * vestibular impairment * peripheral neuropathy * also any contraindications to gvs including: * brain metallic implants * pacemakers * recent brain surgery * skull defect * preceding epileptic seizures * sensitive skin behind the ears. healthy volunteers inclusion criteria: * 40 years old minimum age * consent to taking part in the trial healthy volunteers exclusion criteria: * vestibular impairment * history of medical/psychiatric/neurological disorders * currently taking any psychoactive medication * drunk more than 3 units of alcohol in the past 24 hours

Keywords: stroke galvanic vestibular stimulation
cohort study to assess impact of chemotherapy plus bevacizumab on health related quality of life in first line metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer; Quality of Life

Summary: the primary aim of this french multicenter national study is to assess and compare time to quality of life score deterioration (targeted dimensions : global health, fatigue and emotional functionning of eortc qlqc30 according to the first line chemotherapy associated with bevacizumab in metastatic colorectal patients.


Eligibility criteria:
inclusion criteria: * age\> 18years * metastatic colorectal cancer (non resectable) * 1st chemotherapy including bevacizuman exclusion criteria: * treatment contre-indication

Keywords: bevacizumab health related quality of life
diagnostic performance of plasma procalcitonin for the detection of blood cultures contaminations

Conditions: Blood Culture Contamination; Bacteremia; Contamination

Summary: in blood cultures, species considered as potentially contaminating (coagulase negative staphylococci (cns), bacillus spp., corynebacterium spp., cutibacterium acnes, micrococcus spp., viridans group streptococci, and clostridium perfringens) can, however, be responsable for true bacteremia. blood levels of the prohormone procalcitonin (pct) markedly increase in the early stages of bacterial infections. the aim of our study is to determine the role of plasma pct as a biomarker differentiating blood culture contaminations from true bacteremia.

blood culture contamination is defined by the introduction into of a microorganism into blood culture bottles from either the patient's or healthcare worker's flora, or the immediate environment during specimen collection. species considered as potentially contaminating (coagulase negative staphylococci (cns), bacillus spp., corynebacterium spp., cutibacterium acnes, micrococcus spp., viridans group streptococci, and clostridium perfringens) can, however, be responsible for true bacteremia. if an organism belonging to one of those species is detected in isolates, rapidly and accurately assessing its contaminant or infectious potential is hence important to ensure effective antibiotic therapy as well as to reduce financial burden caused by unnecessary treatments, and additional clinical and laboratory costs. blood levels of the prohormone procalcitonin (pct) markedly increase in the early stages of bacterial infections. the aim of our study is to determine the role of plasma pct as a biomarker differentiating blood culture contaminations from true bacteremia.

Eligibility criteria:
inclusion criteria: * at least one blood culture positive for of the following microorganisms: coagulase negative staphylococci, viridans group streptococci * pct levels measurement on the day of blood culture specimen collection * adult patients exclusion criteria: * patients with less than 3 blood culture bottles collected

Keywords: procalcitonin
primary mediastinal large b-cell lymphoma with cns involvement

Conditions: Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Summary: retrospective study focused on patients with a known diagnosis of pmlbcl which experienced a cns relapse during the course of their disease to obtain information about the clinical characteristics, the management at diagnosis and at each relapses , and the outcome of these cases. the aim of the study is to put together the large international series on cns+ pmlbcl data, coming from 6 different countries , on clinical factors, anti-lymphoma therapy administered alone or concomitant with cns prophylaxis , the information about the site of re biopsy when available , the dose intensity of lymphoma therapy received at relapse and the outcome of patients. both patients treated in routine practice or within clinical trials will be considered. moreover to better characterized the pathological features of this rare entity a central pathological review of the initial diagnosis and when available of for histological confirmed relapse will be considered.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of primary mediastinal large b cell lymphoma (pmlbcl) according who classification * had a recurrence/progression with central nervous system (cns) involvement * availability of details on clinical presentation, treatment details and outcome * availability of details on pathological data for central review * age ≥18 years exclusion criteria * patients with cns lymphoma other than pmlbcl subtype

Keywords: pmbcl cns